The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Open accessAbstract
BACKGROUND: A new approach in the treatment of cystic fibrosis involves improving the function of mutant cystic fibrosis transmembrane conductance regulator (CFTR). VX-770, a CFTR potentiator, has been shown to increase the activity of wild-type and defective cell-surface CFTR in vitro. METHODS: We randomly assigned 39 adults with cystic fibrosis and at least one G551D-CFTR allele to receive oral VX-770 every 12 hours at a dose of 25, 75, or 150 mg or placebo for 14 days (in part 1 of the study) or VX-770 every 12 hours at a dose of 150 or 250 mg or placebo for 28 days (in part 2 of the study). RESULTS: At day 28, in the group of subjects who received 150 mg of VX-770, the median change in the nasal potential difference (in response to the administration of a chloride-free isoproterenol solution) from baseline was -3.5 mV (range, -8.3 to 0.5; P=0.02 for the within-subject comparison, P=0.13 vs. placebo), and the median change in the level of sweat chloride was -59.5 mmol per liter (range, -66.0 to -19.0; P=0.008 within-subject, P=0.02 vs. placebo). The median change from baseline in the percent of predicted forced expiratory volume in 1 second was 8.7% (range, 2.3 to 31.3; P=0.008 for the within-subject comparison, P=0.56 vs. placebo). None of the subjects withdrew from the study. Six severe adverse events occurred in two subjects (diffuse macular rash in one subject and five incidents of elevated blood and urine glucose levels in one subject with diabetes). All severe adverse events resolved without the discontinuation of VX-770. CONCLUSIONS: This study to evaluate the safety and adverse-event profile of VX-770 showed that VX-770 was associated with within-subject improvements in CFTR and lung function. These findings provide support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis. (Funded by Vertex Pharmaceuticals and others; ClinicalTrials.gov number, NCT00457821.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Webb, A. K. (2006) · Cited by 4,369
Spirometric Reference Values from a Sample of the General U.S. Population
HANKINSON, J. L., ODENCRANTZ, J. R., & FEDAN, K. B. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9712108 · Cited by 4,206
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Self-citationRescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
Self-citationFarrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,094
Self-citationDevelopment and Validation of the Cystic Fibrosis Questionnaire in the United States
Quittner, A. L., Buu, A., Messer, M. A., Modi, A. C., & Watrous, M. (2005) · Chest · doi:10.1378/chest.128.4.2347 · Cited by 507
Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J., Aviram, M., Bdolah-Abram, T., Bebok, Z., Shushi, L., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022170 · Cited by 503
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
Alton, E., Stern, M., Farley, R., Jaffe, A., Chadwick, S., Phillips, J., Davies, J., Smith, S., Browning, J., Davies, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06532-5 · Cited by 435
Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M., Nissim-Rafinia, M., Blau, H., Rivlin, J., Aviram, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61168-x · Cited by 403
Quittner, A. L., Modi, A. C., Wainwright, C., Otto, K., Kirihara, J., & Montgomery, A. B. (2009) · Chest · doi:10.1378/chest.08-1190 · Cited by 400
Konstan, M. W., Davis, P. B., Wagener, J. S., Hilliard, K. A., Stern, R. C., Milgram, L. J. H., Kowalczyk, T. H., Hyatt, S. L., Fink, T. L., Gedeon, C. R., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1255 · Cited by 298
Self-citationRelative ion permeability of normal and cystic fibrosis nasal epithelium.
Knowles, M., Gatzy, J., & Boucher, R. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110894 · Cited by 286
An Apical-Membrane Chloride Channel in Human Tracheal Epithelium
Welsh, M. J. (1986) · Science · doi:10.1126/science.2424085 · Cited by 205
Sermet-Gaudelus, I., Renouil, M., Fajac, A., Bidou, L., Parbaille, B., Pierrot, S., Davy, N., Bismuth, E., Reinert, P., Lenoir, G., et al. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-5 · Cited by 160
Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis
Amaral, M. D., & Kunzelmann, K. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.004 · Cited by 142
Rowe, S. M., Accurso, F. J., & Clancy, J. P. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200703-043br · Cited by 87
Self-citationDoes lithium carbonate affect the ion transport abnormality in cystic fibrosis?
Anbar, R. D., Lapey, A., Khaw, K., Spragg, J., Strieder, D. J., Shaw, L. F., Kelly, D. H., & Shannon, D. C. (1990) · Pediatric Pulmonology · doi:10.1002/ppul.1950080205 · Cited by 12
Cited by
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Self-citationCorrection of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105787108 · Cited by 1,088
Self-citationThe future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Self-citationCystic fibrosis genetics: from molecular understanding to clinical application
Cutting, G. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 965
Origins of Cystic Fibrosis Lung Disease
Stoltz, D. A., Meyerholz, D. K., & Welsh, M. J. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300109 · Cited by 669
Metadata
- Authors
- Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M. P., Dunitz, J. M., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., Moss, R. B., Pilewski, J. M., Rubenstein, R. C., Uluer, A. Z., Aitken, M. L., Freedman, S. D., Rose, L. M., Mayer-Hamblett, N., Dong, Q., Zha, J., Stone, A. J., Olson, E. R., Ordoñez, C. L., Campbell, P. W., Ashlock, M. A., & Ramsey, B. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-11-18
- Volume
- 363
- Issue
- 21
- Pages
- 1991-2003
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2121996960
- Cited by
- 807
- References
- 18
- FWCI
- 52.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.